文献速递浆细胞疾病

多发性骨髓瘤循环肿瘤细胞:从外周线索到核心洞察

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.
PubMed 文献 · Am J Hematol · 2026-04-13

循环肿瘤细胞(CTC)是多发性骨髓瘤(MM)液体活检的关键组分,可反映恶性浆细胞逃逸骨髓微环境并全身播散。高灵敏度流式与单细胞测序使CTC精准计数与分子解析可行,CTC定量在诊断时具独立预后价值。CTC基因组/转录组可重现骨髓瘤典型病变并追踪克隆演化,有望成为骨髓MRD之外的互补标志物。

要点

  • CTC定量在诊断时具独立预后价值,低水平亦预示较差生存。
  • CTC基因组/转录组分析可重现骨髓瘤典型病变并追踪克隆演化。
  • CTC持续或再现可提示复发,尤其骨髓MRD阳性患者。

核心结论

  • CTC分析有望从替代生物标志物转变为临床可操作工具,推动MM精准医学。

研究设计与样本

  • 综述类文章,未报告系统检索范围与样本量。

主要发现

  • CTC检测贯穿MGUS、冒烟型骨髓瘤、孤立性浆细胞瘤、症状性MM及浆细胞白血病。
  • 高灵敏度流式细胞术与下一代单细胞测序实现CTC准确计数与分子 interrog 解析。
  • CTC定量在诊断时具独立预后价值,低水平亦预测较差生存。
  • MinimuMM-seq与SWIFT-seq等概念验证研究证实CTC基因组/转录组可重现骨髓瘤典型病变、揭示克隆异质性并追踪治疗下演化动态。
  • CTC持续或再现偶可观察到,存在时可能提示复发,尤其在骨髓MRD阳性患者中。

临床怎么用

  • CTC可作为骨髓MRD评估的互补生物标志物,用于诊断时预后分层与治疗后复发监测。

局限性

  • 方法学挑战仍存,尤其标准化、灵敏度及整合入临床工作流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Circulating tumor cells (CTCs) have emerged as a key component of liquid biopsy in multiple myeloma (MM), reflecting the ability of malignant plasma cells to escape the bone marrow (BM) niche, disseminate systemically, and contribute to disease progression. Their detection in peripheral blood is now feasible across the disease spectrum, from MGUS and smoldering myeloma to solitary plasmacytoma, symptomatic MM, and plasma cell leukemia, providing a dynamic window into tumor biology. Technological advances, including high-sensitivity flow cytometry and next-generation single-cell sequencing, have enabled accurate enumeration and molecular interrogation of CTC. Beyond their biological significance, CTC quantification has consistently demonstrated independent prognostic value at diagnosis, with even low levels predicting inferior survival outcomes. Recent proof-of-concept studies, such as MinimuMM-seq and SWIFT-seq, established that genomic and transcriptomic profiling of CTC can recapitulate canonical myeloma lesions, reveal clonal heterogeneity and track evolutionary dynamics under therapy. Importantly, persistent or reemergent CTC after are occasionally observed and, when present, may signal relapse, particularly, in patients with BM-MRD positivity, highlighting their potential as complementary biomarkers alongside established BM MRD assessment. Although methodological challenges remain-particularly, standardization, sensitivity, and integration into clinical workflows-CTC analysis holds the promise of transforming from a surrogate biomarker to a clinically actionable tool, advancing precision medicine in MM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Podvin B, Paiva B, Ghobrial IM, et al. Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights. Am J Hematol. 2026. PMID: 41974595. doi:10.1002/ajh.70326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。